Authors
Latest:
Misinformation Rampant Among Cancer PatientsCancer patients get inundated with advice, but how much of it can be trusted? Patient advocate Suzie Siegel weighs in.
Latest:
Halt in Production of Codman Pump Leaves QuestionsMSKCC’s Dr. Nancy Kemeny discusses the impact of a company's decision to halt manufacture of a pump used to treat liver mets from colon and rectal cancers.
Latest:
TNM Tumor Staging Revisited: A Look at Updated AJCC GuidelinesUpdates to the 8th edition of AJCC's staging manual include incorporation of more nonanatomic features. Oncology Clinical Specialist Chelsea Backler discussed key changes during the 2018 ONS Congress.
Latest:
How to Build a System-Wide Ambulatory Navigation ProgramAlisa Domb highlighted training and workflow optimization for an ambulatory-setting navigation program covering 10 hem/onc clinics and 2 cancer centers, during the 2018 ONS Congress.
Latest:
ASCO Preview: Lymphoma Presentation HighlightsJoshua Brody discusses ECHELON-1 and its subanalyses, the results of which are anticipated to change the management of Hodgkin lymphoma.
Latest:
ASCO 2018 Highlights: GI and Hepatic Toxicities of Immune Checkpoint Inhibitor TherapyIn this podcast, ASCO Educational Book contributor Dr. Shilpa Grover, from Brigham and Women’s Hospital, describes GI and hepatic AEs encountered in patients on ICI therapy.
Latest:
POINT: Does Chemoimmunotherapy Still Have a Role in CLL?Until the superiority of novel agents is proven for all prognostically relevant subgroups of patients with CLL, we believe chemoimmunotherapy continues to have a role.
Latest:
POINT: Does Chemoimmunotherapy Still Have a Role in CLL?Until the superiority of novel agents is proven for all prognostically relevant subgroups of patients with CLL, we believe chemoimmunotherapy continues to have a role.
Latest:
Jennifer A. Woyach, MD, Discusses Use of Ibrutinib in CLL at 2021 ASHJennifer A. Woyach, MD, spoke about why it’s important to use newer therapies instead of chemoimmunotherapy for patients with chronic lymphocytic leukemia.
Latest:
Management of Gastrointestinal Toxicities From Ixazomib: Tips to Curb Nausea, Vomiting, Diarrhea, and ConstipationAn oncology pharmacist discusses how to manage GI toxicities in multiple myeloma patients.
Latest:
Kelly Valla, PharmD, BCOP, on Secondary Malignancies With Tazemetostat for Follicular LymphomaAn oncology pharmacist talks secondary malignancies noted with tazemetostat in the treatment of follicular lymphoma.
Latest:
Understanding the Benefits of Acupuncture Treatment for Cancer Pain ManagementThis article reviews how acupuncture is thought to work, data on acupuncture for managing pain caused by cancer or by cancer treatment, how acupuncture is practiced in the US medical system, discussion of safety issues, and practical tips on how to integrate acupuncture into cancer care.
Latest:
A 35-Year-Old Woman With a Change in HER2 Expression Following Neoadjuvant Chemotherapy for Invasive Breast CancerA 35-year-old woman noticed a mass in her right breast and underwent a diagnostic workup, including a mammogram that revealed a 2.4-cm mass and ultrasound that showed two adjacent masses, as well as enlarged axillary lymph nodes.
Latest:
A 35-Year-Old Woman With a Change in HER2 Expression Following Neoadjuvant Chemotherapy for Invasive Breast CancerA 35-year-old woman noticed a mass in her right breast and underwent a diagnostic workup, including a mammogram that revealed a 2.4-cm mass and ultrasound that showed two adjacent masses, as well as enlarged axillary lymph nodes.
Latest:
Highlights of USPSTF Updates to Prostate Cancer Screening GuidelinesUSPSTF Vice-Chair Alex Krist and prostate cancer specialist David Penson shared perspectives on USPSTF’s updated prostate cancer screening recommendation.
Latest:
How LGL T-Cell Leukemia at 19 Gave Me Empathy for My Patients-and My ColleaguesLate last year, ONCOLOGY hosted a writing contest on Cancer Network, in which we asked our readers to share their personal experiences with delivering bad news. Dr. Trevor Bayliss submitted a piece about his experience as a young patient, and how that influenced his decision to become an oncologist.
Latest:
Exploring the Changing Landscape of ICI Tx in NSCLCIn this video, Dr. Leena Gandhi discusses KEYNOTE-042, a study of pembrolizumab vs chemotherapy in NSCLC (abstract LBA4), and other key ICI trials reported at ASCO 2018.
Latest:
Newer Targeted Approaches in Medullary Thyroid CancerIn this video, Dr. Manisha Shah highlights new and emerging targeted therapies for medullary thyroid cancer, including research presented at ASCO 2018.
Latest:
What Caused This Ulcerated Nodular Skin Lesion in a 30-Year-Old Man?This lesion started as a rash 3 months prior to presentation and became an ulcerated open wound with some nodularity in and around it. What is your diagnosis?
Latest:
Cell-Free DNA Blood Test May Detect Early-Stage Lung CancerCell-free DNA, used to guide treatment of advanced lung cancer, may become a tool for early detection, based on analysis of participants in the Circulating Cell-free Genome Atlas study.
Latest:
Dr. Daniel George on the Treatment Landscape for RCCCancer Network spoke with Daniel George, MD, of Duke Health, about the treatment landscape and current trials for renal cell carcinoma.
Latest:
Newer Targeted Agents in NSCLC: ALK InhibitorsAlice Shaw highlights the development and clinical considerations for use of first- and next-generation ALK inhibitors in NSCLC, plus ongoing research.
Latest:
Andrew J. Armstrong, MD, Details PSMA-PET Scan Parameters Indicating Better Survival Outcomes With 177Lu-PSMA-617 in mCRPCData from a substudy of the phase 3 VISION trial presented at 2022 ASCO Annual Meeting showed that higher standard mean uptake value by PSMA-PET is strongly associated with outcomes for patients with metastatic castration-resistant prostate cancer.
Latest:
Newer Targeted Agents in NSCLC: TAK-788, an EGFR and HER2 InhibitorRobert Doebele discusses TAK-788, a first-in-class inhibitor of both EGFR and HER2 shown in an early-phase study to be active in NSCLC.
Latest:
Acute Kidney Injury in Patients With CancerAcute kidney injury is a common complication in cancer patients, and clinicians should be familiar with the processes that cause it.
Latest:
Sharing Serious News With Cancer Patients: Strategies That Can HelpThe way in which serious news is discussed significantly affects many outcomes and aspects of patient care. It is important to consider many factors, including those related to patient diversity, such as cultural and family background; language barriers; socioeconomic factors; and health literacy.
Latest:
Sharing Serious News With Cancer Patients: Strategies That Can HelpThe way in which serious news is discussed significantly affects many outcomes and aspects of patient care. It is important to consider many factors, including those related to patient diversity, such as cultural and family background; language barriers; socioeconomic factors; and health literacy.
Latest:
Post-Prostatectomy Radiation Therapy: Patient Selection, Timing, Imaging, and Therapy IntensificationA 62-year-old man with prostate adenocarcinoma elected to proceed with radical prostatectomy as definitive management. After his pathology report showed stage IIIB disease, he elected for observation. What happened next?
Latest:
Post-Prostatectomy Radiation Therapy: Patient Selection, Timing, Imaging, and Therapy IntensificationA 62-year-old man with prostate adenocarcinoma elected to proceed with radical prostatectomy as definitive management. After his pathology report showed stage IIIB disease, he elected for observation. What happened next?
